Literature DB >> 6305498

Efficacy of "two-route chemotherapy" using intra-arterial cisplatin and iv sodium thiosulfate, its antidote, in rat bladder tumor.

K Sagiyama, J Uozumi, K Aoki, T Baba.   

Abstract

The efficacy of "two-route chemotherapy (TRC)" using a combination of cisplatin (DDP) and its antidote, sodium thiosulfate (STS), was evaluated in rat bladder tumor. TRC in which 20 mg/kg of DDP and two doses of 1054 mg/kg of STS (100-fold molar ratio to DDP) were given during interruption of arterial flow for 30 minutes through the abdominal aorta and femoral vein, respectively, provided significantly better antitumor effects evaluated by tumor weight and survival time than did intra-arterial or iv DDP (4 mg/kg) without STS. These three modalities revealed a similar toxicity in rats. Dose- and time-related efficacy of DDP and a high sensitivity of a transitional cell carcinoma of the rat to DDP were noted in TRC. Nephrotoxicity assessed by increase in BUN levels was minimum. The particular combination of intra-arterial DDP and iv STS presented here is applicable to regionally confined human bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305498

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  15 in total

1.  Protection of antiproliferative effect of cis-diamminedichloroplatinum (II) by sodium thiosulfate.

Authors:  R Abe; T Akiyoshi; H Tsuji; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Experiences with sodium thiosulfate after intracarotid infusion of cisplatin and BCNU for malignant gliomas.

Authors:  R B Vance; J Pittisapu; J P Kapp
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

3.  "Two-route chemotherapy" using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, combined with angiotensin II is effective against peritoneally disseminated cancer in rats.

Authors:  H Kobayashi; K Hasuda; K Aoki; T Kuroiwa; S Taniguchi; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in guinea pigs.

Authors:  T Saito; Z J Zhang; Y Manabe; T Ohtsubo; H Saito
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

5.  Balloon-occluded arterial infusion therapy in the treatment of primary and recurrent gynecologic malignancies.

Authors:  Y Yamashita; M Takahashi; H Bussaka; Y Korogi; R Saito; K Miyazaki; S Fujisaki; H Okamura
Journal:  Cardiovasc Intervent Radiol       Date:  1989 Jul-Aug       Impact factor: 2.740

6.  Increased therapeutic effect on metastatic liver tumors in rats of two-route chemotherapy using cis-diamminedichloroplatinum (II) and its antidote, sodium thiosulfate, with temporary clamping of the abdominal aorta.

Authors:  K Hasuda; H Kobayashi; K Aoki; S Taniguchi; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Inactivation of cis-diamminedichloroplatinum (II) in blood and protection of its toxicity by sodium thiosulfate in rabbits.

Authors:  Y Iwamoto; T Kawano; M Ishizawa; K Aoki; T Kuroiwa; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Sodium thiosulfate inhibits cis-diamminedichloroplatinum (II) activity.

Authors:  J Uozumi; M Ishizawa; Y Iwamoto; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

9.  Upper hemibody infusion of cis-diamminedichloroplatinum (II) followed by systemic antidote, sodium thiosulfate, for lung metastasis in rats.

Authors:  Y Iwamoto; K Aoki; T Kawano; T Baba
Journal:  Clin Exp Metastasis       Date:  1984 Jul-Sep       Impact factor: 5.150

10.  Experimental and clinical studies on the intraperitoneal administration of cis-diamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers.

Authors:  T Furukawa; K Kumai; T Kubota; S Hirahata; H Shimizu; H Matsui; T Takahara; K Aizawa; S Shibata; A Shimada
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.